IPSEN |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 115.3 EUR | +3.50% |
|
+8.27% | +6.77% |
| 08:57am | Ipsen: sales up 11% in Q1 | CF |
| Apr. 22 | Ipsen Teams Up with Skyhawk Therapeutics on Study of RNA Modulator for Rare Neurological Diseases | MT |
| Sales 2024 * | 3.44B 3.68B | Sales 2025 * | 3.68B 3.93B | Capitalization | 9.2B 9.84B |
|---|---|---|---|---|---|
| Net income 2024 * | 636M 680M | Net income 2025 * | 708M 757M | EV / Sales 2024 * | 2.5 x |
| Net cash position 2024 * | 606M 648M | Net cash position 2025 * | 1.27B 1.36B | EV / Sales 2025 * | 2.16 x |
| P/E ratio 2024 * |
14.6
x | P/E ratio 2025 * |
13.2
x | Employees | 5,325 |
| Yield 2024 * |
1.08% | Yield 2025 * |
1.09% | Free-Float | 41.52% |
More Fundamentals
* Assessed data
More news
Latest transcript on Ipsen
More press releases
More news
| 1 day | +3.32% | ||
| 1 week | +8.18% | ||
| Current month | +4.35% | ||
| 1 month | +5.11% | ||
| 3 months | +6.77% | ||
| 6 months | -2.70% | ||
| Current year | +6.67% |
1 week
105.30
115.40
1 month
104.60115.40
Current year
99.70115.40
1 year
99.70130.70
3 years
77.00130.70
5 years
34.20130.70
10 years
30.67155.95
| Managers | Title | Age | Since |
|---|---|---|---|
David Loew
CEO | Chief Executive Officer | 57 | 20-06-30 |
| Director of Finance/CFO | 54 | 14-11-02 | |
| Chairman | 66 | 10-11-21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Margaret Liu
BRD | Director/Board Member | 66 | 17-06-06 |
Karen Witts
BRD | Director/Board Member | 61 | 22-01-20 |
Michèle Ollier
BRD | Director/Board Member | 65 | 15-05-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.83% | 2 M€ | +8.60% | ||
| 0.43% | 182 M€ | +7.29% | ||
| 0.31% | 3 M€ | +9.95% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 115.3 | +3.50% | 21 946 |
| 24-04-23 | 111.4 | -0.98% | 72,843 |
| 24-04-22 | 112.5 | +3.78% | 115,703 |
| 24-04-19 | 108.4 | +1.98% | 61,254 |
| 24-04-18 | 106.3 | -0.09% | 48,574 |
Real-time Euronext Paris, April 24, 2024 at 03:58 am EDT
More quotes
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows:
- oncology (75.2%);
- neuroscience (21.1%);
- rare diseases (3.7%).
At the end of 2023, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide.
Net sales are distributed geographically as follows: Europe (40.2%), North America (33.3%) and other (26.5%).
Sector
Pharmaceuticals
Calendar
07:00am
- Q1 2024 Sales and Revenue Call
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
111.4
EUR
Average target price
124.6
EUR
Spread / Average Target
+11.87%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.67% | 9.85B | |
| +27.92% | 672B | |
| +26.97% | 570B | |
| -4.59% | 360B | |
| +16.38% | 321B | |
| +9.39% | 300B | |
| +7.26% | 217B | |
| +5.61% | 199B | |
| -8.47% | 204B | |
| -8.58% | 149B |
- Stock Market
- Equities
- IPN Stock
